Norda ASA Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2012
February 28, 2013 at 03:17 am EST
Share
Norda ASA reported unaudited earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company reported total operating revenues of NOK 46,000 compared with NOK 987,000 for the same period a year ago. LBITDA was NOK 1,061,000 compared with NOK 714,000 for the same period a year ago. LBIT was NOK 1,061,000 compared with NOK 739,000 for the same period a year ago. Loss before tax was NOK 1,883,000 compared with NOK 731,000 for the same period a year ago. Loss from continuing operations was NOK 1,883,000 compared with NOK 731,000 for the same period a year ago. Loss attributable to equity holders of the company was NOK 2,713,000 or NOK 0.7 per share compared with NOK 56,626,000 or NOK 0.7 per share for the same period a year ago. Net cash from operating activities was NOK 891,000 compared with net cash used in operating activities of NOK 5,196,000 for the same period a year ago. Net cash from operating activities from continuing operations was NOK 1,658,000 compared with net cash used in operating activities from continuing operations of NOK 31,000 for the same period a year ago.
For the year, the company reported total operating revenues of NOK 645,000 compared with NOK 1,830,000 for the same period a year ago. LBITDA was NOK 7,009,000 compared with NOK 4,281,000 for the same period a year ago. LBIT was NOK 7,074,000 compared with NOK 4,354,000 for the same period a year ago. Loss before tax was NOK 7,043,000 compared with NOK 4,514,000 for the same period a year ago. Loss from continuing operations was NOK 7,043,000 compared with NOK 4,514,000 for the same period a year ago. Loss attributable to equity holders of the company was NOK 10,115,000 or NOK 2.5 per share compared with NOK 89,329,000 or NOK 5.9 per share for the same period a year ago. Net cash used in operating activities was NOK 27,246,000 compared with NOK 30,260,000 for the same period a year ago. Net cash used in operating activities from continuing operations was NOK 5,325,000 against NOK 3,542,000 a year ago.
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Companyâs products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
NORDA ASA 
